Below are approved quotes from the ISTH leadership and experts in the field of thrombosis, hemostasis, and vascular biology. In addition to supplying press materials, we are also happy to arrange 1:1 interviews. If interested in arranging, please get in touch with ISTH Media Relations Manager, Melissa DiMercurio melissa_dimercurio@isth.org

**Our Commitment: Leading the Way in Thrombotic and Bleeding Disorders**

**Thomas Reiser,**
ISTH Executive Director

“This year’s congress in London will be one of the most impactful events for our international medical-scientific community. ISTH will again be the congress where transformative scientific discoveries and new clinical applications are shared and it will be the first time that the international thrombosis and hemostasis community will again convene in-person since 2019. While the pandemic certainly posed challenges for our and many other organizations, we did successfully launch a robust virtual platform which will now complement our in-person meeting and thereby allow us to engage in a more meaningful way with a wider global community and create new opportunities for scientific exchange and advancement. We look forward to continuing to innovate and providing our members and participants with a more elevated experience in 2022 and beyond.”

**This Year’s ISTH 2022 Congress and World Thrombosis Day Chair**

**Beverley Hunt, M.D. O.B.E**
Chair of the ISTH 2022 Congress Local Organizing Committee, and Chair of the World Thrombosis Day Scientific Steering Committee

“On behalf of the ISTH 2022 Congress Local Organizing Committee, we are thrilled to have the opportunity to welcome clinicians, researchers, educators and experts in thrombosis and bleeding from around the world to London. With an expected attendance of many thousands of delegates from more than 100 countries, attending mainly in-person, as well as virtually, the congress will be the most significant scientific meetings in thrombosis and haemostasis since the start of the pandemic. We will be discussing the high rates of thrombosis seen in the pandemic and hear from world-renowned experts that have submitted abstracts on new work in other areas, such as haemorrhagic disorders, thromboembolism and new understanding of how coagulation works and can cause disease.”

**Spotlight on World Thrombosis Day**

“The ISTH has always been and will continue to be a pioneer in sparking attention on the often overlooked and misunderstood condition of thrombosis. In a similar spirit to World Thrombosis Day’s efforts to initiate conversations on a global scale among different audiences, the ISTH 2022 Congress’s creative, educational offerings allow delegates from all over the world to follow and share new scientific developments and collectively initiate progress in treatment and diagnosis.”

**ISTH Council Leadership**
Jeffery Weitz, M.D.
Former ISTH President 2020-2022 term

“The ISTH is committed to providing the latest innovations in scientific meetings and we continue to explore creative and exciting offerings for our delegates. Innovations such as a robust virtual component combined with in-person sessions reflect the ISTH’s overall focus on delivering knowledge and education in new ways to best meet the needs of scientists and clinicians around the world.”

Flora Peyvandi, M.D., Ph.D.
ISTH President 2022-2024 term

“The ISTH 2022 Congress is still in full swing in London, but we are already focused on future-oriented engagement and collaboration because that is what is required to stay at the forefront of medical innovation. These discussions will propel us forward as well as prepare our community for ISTH 2023 Congress in Montréal. Together, with our strong global leadership, the ISTH will build upon past successes and keep focusing on strengthening education offerings to enhance clinical and laboratory research as well as patient care.”

Pantep Angchaisuksiri, M.D.
Elected ISTH President 2024-2026 term

“True to the ISTH’s commitment to support and foster transformative scientific research as well as clinical practices, the ISTH 2022 Congress provides young professionals with different mentorship opportunities such as networking lounges and master classes. This is a testament to the ISTH’s long-standing dedication to investing in the training and education of early career professionals and building strong competencies through programs and opportunities such as the ISTH Academy, Reach-the-World fellowships and workshops.”
Marc Carrier, M.D.
2022 Chair of the Scientific and Standardization Committee (SSC)

“We are currently in the midst of a special time of year, during which an opportunity exists to join the leadership of the Scientific and Standardization Committee (SSC), a dynamic group comprised of several thousand ISTH members that collaborate to recommend standards relevant to the fields of thrombosis and hemostasis. Many of the developments are adopted by the World Health Organization (WHO) as International Standards. Annually this SSC call for applications provides members with an opportunity for leadership and a unique platform to share perspectives and experiences.”

Joost Meijers, M.D.
Incoming Chair of the Scientific and Standardization Committee (SSC)

“This year the SSC led the launch of ISTH’s new “My ISTH Community” platform, a community engagement system that allows each SSC Subcommittee to connect via online forums and working groups. From the newest member to the Subcommitee’s Chair, all may post ideas, request feedback and use this tool to advance the Subcommittee’s work. The “My ISTH Community” platform details will be sharing with members at the ISTH 2022 Congress, and launched society-wide soon by the SSC which reflects yet another great opportunity created by the Society to connect, collaborate and innovate.”

Sam Schulman, M.D., Ph.D.
Incoming Chair of the Scientific and Standardization Committee (SSC)

“This year during Congress, the ISTH is sharing its COVID guidelines which provide 12 recommendations based on high or moderate-quality evidence available through March 2022 that are inclusive for all countries. For non-critically ill, hospitalized patients, there is a strong recommendation for use a of prophylactic dose low-molecular-weight heparin or unfractionated heparin (LMWH/UFH), whereas for select patients in this group, a therapeutic dose of LMWH/UFH is recommended rather than prophylactic dose, but a strong recommendation against the addition of an antiplatelet agent. Weaker recommendations are given for or against antithrombotic for non-hospitalized, for hospitalized critically ill and for patients discharged from the hospital. The guidelines are accompanied by a Good Practice Statement document with additional suggestions in areas where only low-quality evidence is available.”
James Morrissey, Ph.D.
Co-Editor-in-Chief of Journal of Thrombosis and Haemostasis (JTH)

“As one of the most important biomedical meetings advancing science in the areas of thrombosis, hemostasis and vascular biology, the ISTH 2022 Congress promotes dissemination and exchange of the latest findings within the international research community. Contributions from this year’s congress will be featured in the Journal of Thrombosis and Haemostasis (JTH), the flagship journal of the ISTH.”

David Lillicrap, M.D.
Co-Editor-in-Chief of Journal of Thrombosis and Haemostasis (JTH)

“As the leading international medical and scientific society in the area of thrombotic and bleeding disorders, ISTH is committed to finding new scientific solutions for existing challenges and unmet needs in the field. The ISTH Congress is traditionally dedicated to unveiling new diagnostics and therapeutic approaches, and this year’s congress in London will be one of the most impactful events in terms of transformative scientific discoveries and new clinical applications.”

Mary Cushman, M.D.
Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis (RPTH)

“This year marks the fifth anniversary of Research and Practice in Thrombosis and Haemostasis (RPTH), an open access and online only publication, which was first launched at the ISTH 2017 Congress. The journal was accepted into the Science Citation Index Expanded (SCIE) qualifying it to receive its first Impact Factor this year, a significant testament to the associate editors, editorial board, authors and peer reviewers who have participated with us on this journey so far. We look forward to a bright future for RPTH and its position in the science publishing landscape that continues to grow with the support of the thrombosis and hemostasis community.”